Study of a New Treatment Called TNG348 in People with Advanced or Metastatic Cancer and with a BRCA1 or BRCA2 Mutation or HRD Positive Tumor
https://www.facingourrisk.org/research-clinical-trials/study/296/study-of-a-new-treatment-called-tng348-in-people-with-advanced-or-metastatic-cancer-and-with-a-brca1-or-brca2-mutation-or-hrd-positive-tumor
Clinicaltrials.gov identifier:
NCT06065059 (https://clinicaltrials.gov/show/NCT06065059)
Treatment for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor
Study Contact Information:
About the Study
This study is no longer recruiting patients.
The study will test the safety and effectiveness of a new drug called TNG348 used alone or in combination with Olaparib (a PARP inhibitor.) The study is for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor.
This Study is Open To:
This study is no longer recruiting patients.
This Study is Not Open To:
This study is no longer recruiting patients.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.